Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070247 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT05070247 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 61 participants.
The verdict
NCT05070247, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: * to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. * to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.
Interventions
- DRUG Pembrolizumab
- DRUG Dexamethasone
- DRUG Tocilizumab
- DRUG TAK-500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2025-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070247
The ClinicalTrials.gov registry entry for NCT05070247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05070247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05070247 about?
NCT05070247 is a clinical study titled "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors". This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: * to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. * to assess the anti-tumor effects of T...
What is the current status of trial NCT05070247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-04-14. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT05070247?
The interventions under investigation include: Pembrolizumab (DRUG), Dexamethasone (DRUG), Tocilizumab (DRUG), TAK-500 (DRUG).
Who is sponsoring clinical trial NCT05070247?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.